Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2014—Medical experts representing Vermillion, a multivariate diagnostics company focused on gynecologic cancers and women’s health, presented on Aspira Labs, its new CLIA-certified reference laboratory. Aspira Labs provides expert diagnostic services, including OVA1 and Longitudinal CA 125 testing, which support clinical decision-making and personalized treatment plans.
September 2014—Biofortuna announced the expansion of its freeze-dried production service. Biofortuna invested in a new, state-of-the-art freeze-drier and additional climate-control units to meet the increased demands of companies that are outsourcing their freeze-dried production of diagnostic kits. The additional freeze-drier and infrastructure almost doubles the company’s production capacity.
September 2014—Pall Life Sciences’ Acrodisc WBC premium syringe filter is a filtration device designed specifically for use in the capture and recovery of leukocytes and the separation of red blood cells. The Acrodisc WBC filter contains the company’s patented Leukosorb media.
September 2014—Eco-Tek products by Kem-En-Tec, distributed in the U.S. by Rainbow Scientific, reduce the environmental impact of ELISA, blotting, or immunohistochemistry applications by eliminating biological and chemical hazards commonly found in diagnostic assay components, including bovine serum albumin, sodium azide, and harmful organic solvents, without compromising quality, reliability, or stability.
September 2014—Diagnostica Stago celebrated the success of its newest instrument line with the competitive conversion placement of its 100th Compact Max in six months. The Compact Max, an intelligent, user-friendly platform for coagulation testing, is the first of the Max line of instruments that will be rolling out to laboratories worldwide over the next couple of years.
September 2014—The Mix&Go product is a proprietary surface coating for use in diagnostic testing from Anteo Diagnostics. Mix&Go incorporates a type of molecular Velcro that provides a novel approach for attaching fragile proteins to synthetic surfaces distinct to the traditional methods, enabling the development of sensitive and affordable diagnostics.
September 2014—The promises and perils of big data and mobile health were among the hot topics at this year’s meeting of the American Association for Clinical Chemistry.
August 2014—The Clinical and Laboratory Standards Institute published H52-A2—Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition. This standard addresses the diagnostic red blood cell assays performed as fluorescence-based assays on a flow cytometry platform, including testing procedures for fetomaternal hemorrhage detection, paroxysmal nocturnal hematuria screening, membrane defect anemia testing for hereditary spherocytosis, and nucleated RBC counting. Caveats of interpretation and points of validation and quality control are also discussed.
August 2014—Primera’s Signature Cassette Printer prints high-resolution text and graphics along with linear and 2D bar codes directly onto tissue cassettes. The printer has four cassette hoppers, each holding 40 cassettes, and can print up to 11 cassettes per minute.
August 2014—SeraCare Life Sciences released four research panels that deliver hard-to-find material for hepatitis C, Chagas, and dengue.
